



HAL
open science

Pathophysiological mechanisms of autoimmunity

Muriel Sudres, Julien Verdier, Frédérique Truffault, Rozen Le Panse, Sonia Berrih-Aknin

► **To cite this version:**

Muriel Sudres, Julien Verdier, Frédérique Truffault, Rozen Le Panse, Sonia Berrih-Aknin. Pathophysiological mechanisms of autoimmunity. *Annals of the New York Academy of Sciences*, 2018, Myasthenia Gravis and Related Disorders II, 1413, pp.59-68. 10.1111/nyas.13560 . hal-01817720

HAL Id: hal-01817720

<https://hal.sorbonne-universite.fr/hal-01817720v1>

Submitted on 18 Jun 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1
2
3 Short title: Introduction to Autoimmunity
4
5

6
7 **PATHOPHYSIOLOGICAL MECHANISMS OF**
8 **AUTOIMMUNITY**
9

10
11 Muriel Sudres^{1,2,3}, Julien Verdier^{1,2,3}, Frédérique Truffault^{1,2,3}, Rozen Le Panse^{1,2,3} and Sonia
12 Berrih-Aknin^{1,2,3*}
13

14
15
16 ¹ INSERM U974, Paris, France

17 ² UPMC Sorbonne Universités, Paris, France

18 ³ AIM, Institut de myologie, Paris, France
19

20
21
22 * Corresponding author:

23 Sonia Berrih-Aknin

24 UMRS 974 - UPMC Sorbonne Universities - INSERM – AIM

25 Center of Research in Myology

26 105, Boulevard de l'Hôpital

27 75013 PARIS - FRANCE

28 Tel 0033 (0)1 40 77 81 28 Fax 0033 (0)1 40 77 81 29

29 Sonia.berrih-aknin@upmc.fr
30
31
32

33
34
35
36 *Key words: Germinal centers, genetics, triggering factors, inflammation, chronicity, Treg cells*
37

38
39 *Abbreviations:* AChR: acetylcholine receptor
40 AID: autoimmune disease
41 BAFF: B-cell activating factor
42 eQTL: expression quantitative trait loci
43 EOMG: early-onset myasthenia gravis
44 GC: germinal center
45 MG: myasthenia gravis
46 Poly(I:C): polyinosinic-polycytidylic acid
47 PTPN22: Protein tyrosine phosphatase, non-receptor type 22
48 RA: Rheumatoid Arthritis
49 SLE: Systemic lupus erythematosus
50 TLR: Toll-like receptor
51 TNF: Tumor Necrosis Factor
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Autoimmune diseases (AIDs) are chronic disorders characterized by inflammatory reactions against self-antigens that can either be systemic or organ-specific. AIDs can differ in their epidemiologic features and clinical presentations, yet all share a remarkable complexity. AIDs result from an interplay of genetic and epigenetic factors with environmental components that are associated with imbalances in the immune system. Many of the pathogenic mechanisms of AIDs are also implicated in Myasthenia Gravis (MG), an autoimmune disease where inflammation of the thymus leads to a neuromuscular disorder.

The goal of this review is to highlight the similarities and differences between MG and other AIDs by reviewing the common transcriptome signatures and the development of germinal centers, and by discussing some unsolved questions about autoimmune mechanisms. This review will propose hypotheses to explain the origin of regulatory T (Treg) cell defects and the causes of chronicity and specificity of AIDs.

1. Introduction

Autoimmune diseases (AIDs) encompass more than 80 distinct chronic disorders characterized by inflammatory reactions that can either be systemic or organ-specific. Despite decades of research on AIDs and improvement of therapeutic approaches, their exact etiologies remain a conundrum. However, most recent findings suggest that AIDs result from the complex interplay of various factors (genetic, epigenetic, external factors as well as internal components under the influence of environmental factors). While these factors are not sufficient to induce AIDs when taken individually, their temporal combinations may pave the winding road to autoimmunity.

There are many similarities between the different AIDs, and polyautoimmunity is common in patients with AIDs and their families [1]. In all cases, the disease development is the consequence of the effects of environmental factors in predisposed individuals. Predisposing factors could be genetic or non-genetic. Various predisposing genes are shared between several AIDs, suggesting a partial redundancy between these different diseases. Most of the genes identified by genome-wide association studies on AIDs are related to immunity. However, functional immune parameters that are commonly dysregulated in AIDs do not necessarily stem from these genetic variants, as some of them may be directly induced by non-genetic (environmental) triggering events. This was notably illustrated in reports on monozygotic (MZ) discordant twins [2], showing that predisposing genes are not sufficient to develop an AID, and that environmental factors are needed. Environmental cues include predisposing factors (low vitamin D, smoking, pollution, sexual hormones) and triggering factors (specific drugs) as well [1]. Several factors frequently associated with AIDs are illustrated in a word cloud representation (**Figure 1**).

Many of the pathogenic mechanisms of AIDs are also implicated in Myasthenia Gravis (MG). Indeed, MG is multifactorial, and its onset is a consequence of interactions between various genetic and environmental risk factors. The goal of this review is to highlight the similarities and differences between MG and other AIDs such as the common transcriptome signatures, the development of GCs and the overexpression of BAFF. We will also discuss some unsolved questions about autoimmune mechanisms such as the origin of regulatory T (Treg) cell defects. Indeed, although defects of the

1
2
3 immune system are known for long whether they pre-exist in patients before the onset of the disease or
4 are induced by triggering events deserves to be discussed. This review will also propose hypotheses to
5 explain why AIDs are chronic and how the specificity of an AID is determined.
6
7
8
9

10 11 **2. Typical molecular signatures in MG and other AIDs**

12
13
14 At the molecular scale, transcriptomics has largely contributed to identifying pathogenic signatures in
15 human autoimmunity. In early-onset myasthenia gravis (EOMG), the transcriptome of thymuses,
16 which is the inflammatory organ in this disease, was compared with sex- and aged-matched non-MG
17 thymuses [3] [4]. Briefly, the gene hit lists were established as reported [3] and submitted to David
18 Bioinformatic resources [5]. Similarities were found in the category of “Genetic Association
19 Database” that contains genetic association data from complex disorders. This analysis, shown in
20 **Table 1**, involves several AIDs such as systemic lupus erythematosus (SLE), Sjogren's syndrome,
21 thyroiditis or multiple sclerosis [4]. It is noteworthy that these similarities exist despite differences in
22 the immunological mechanisms involved in these diseases [6].
23
24
25
26
27
28
29
30
31
32

33 A similar analysis of the transcriptome of purified thymic Treg and conventional T (Tconv) cells from
34 MG patients in comparison with control cells reveals a 10-fold upregulation of genes known to be
35 involved in other AIDs, such as Type 1 diabetes and autoimmune thyroiditis, and in pathological states
36 associated with increased immune activation and inflammation, such as allograft rejection and graft-
37 versus-host disease [7]. These data suggest that T cells contribute to the similarities between MG and
38 the other AIDs.
39
40
41
42
43
44
45

46 *The genes involved in the ten autoimmune diseases listed in Table 1 were analyzed to detect the genes*
47 *shared between these disorders. We identified 16 genes dysregulated in the thymus of EOMG patients*
48 *as well as in at least three other different AIDs (Table 2).* These include many genes related to the
49 immune response: HLA-DR and DQ, CD14 (monocytes), CD19 (B cells), CD80 (a costimulatory
50 molecule), IL-1 β (a cytokine) and CCL-5/RANTES (a chemokine), but also a gene involved in
51 oxidative stress (NOS) and the protein tyrosine phosphatase, non-receptor type 22 (PTPN22). These
52
53
54
55
56
57
58
59
60

1
2
3 genes are expressed in other cells than T cells, suggesting that not only T cells but also other immune
4
5 cell types are involved in MG. Most of these genes have a genetic association with MG [8]. The
6
7 discovery that the level of expression of these genes is dysregulated in MG thymus suggests the
8
9 presence of genetic regulators of transcription. Indeed, the combined analysis of transcriptomes and
10
11 whole-genomes showed that the expression level of some genes could be regulated by DNA sequence
12
13 variants localized in distinct genomic regions. These variants, named eQTL (Expression quantitative
14
15 trait loci), provide a functional relevance for the association between genetic variants and AIDs. The
16
17 eQTL analysis was recently applied to rheumatoid arthritis (RA) and successfully predicted the
18
19 importance of the Tumor Necrosis Factor (TNF) pathway in CD4+ T cells [9]. Although eQTLs have
20
21 never been studied directly for MG, a screen of cis-eQTLs for 353 AIDs risk variants in 42 human
22
23 thymic tissues identified eight eQTLs associated with seven genetic regions including two regions that
24
25 were thymus-specific [10]. Overall, rather than performing even larger GWAS, understanding
26
27 complex traits such as human diseases may require the meticulous analysis of cell-specific gene
28
29 networks and take into account not only core genes but also seemingly irrelevant genes that may
30
31 overall have an impact on the disease [11].
32

33
34 Among the genes highly associated with AIDs, the most striking ones are HLA-DR1 and PTPN22. We
35
36 will discuss here the potential role of PTPN22 as this gene is genetically linked to more than twenty
37
38 AIDs [12], including MG [13]. PTPN22 is a potent inhibitor of the T-cell receptor signaling pathway
39
40 [14]. In PTPN22 knock-out (KO) mice, effector-memory T cells cause lymphadenopathy,
41
42 splenomegaly, and more germinal centers. High serum concentrations of antibodies are also found in
43
44 these mice [15]. In humans, a single base change in the coding region of this gene (C1858T) is
45
46 observed at a high frequency in patients with AIDs [16]. Consequently, the autoimmune disease
47
48 incidence is 2.5-fold higher in carriers of the C1858T mutation compared to individuals without the
49
50 mutation. This mutation is associated with a decrease in TCR and BCR signaling [17]. The expression
51
52 of PTPN22 was found to be reduced in the MG thymus compared with controls, but the sequence of
53
54 PTPN22 gene was not investigated in these samples. Akin to the data observed in PTPN22 KO mice
55
56
57
58
59
60

1
2
3 [18], the decreased expression of PTPN22 in the thymus of MG patients could be related to the
4
5 increased B cell number and GCs.
6
7

8 9 10 **3. Ectopic germinal centers and autoimmunity**

11
12 In physiological conditions, B-cell activation and differentiation into antibody (Ab)-producing cells
13
14 takes place in secondary lymphoid organs where activated B cells initiate a germinal center (GC)
15
16 reaction and undergo the processes of somatic hypermutation and class switch recombination of the
17
18 immunoglobulin genes. Follicular B cells require T cell help and are the primary source of long-lived
19
20 plasma cells and memory B cells [19].
21

22
23 GCs generally develop ectopically in the target organ in antibody-mediated AIDs [20]. MG is an
24
25 exception as the development of GCs is in the thymus, and not in the muscle that is the target organ
26
27 (**Table 3**). GCs are found in many AIDs such as Sjogren's syndrome, RA, Hashimoto's thyroiditis,
28
29 SLE, multiple sclerosis, primary biliary cirrhosis, as well as dermatomyositis and polymyositis
30
31 (Reviewed in [6]). Surprisingly, the development of GCs in the thymus of MG patients is not a general
32
33 MG feature as it occurs mainly in young female patients with anti-AChR antibodies [21], but not in
34
35 patients with anti-Muscle Specific Kinase (MuSK) antibodies [22]. The reason for this difference is
36
37 still poorly understood.
38

39
40 The generation of GCs is very similar in all AIDs as it is associated with chemokine overproduction
41
42 (CXCL13, CCL21, CCL19, CXCL12)[23], and active angiogenesis involving high endothelial venules
43
44 (HEVs) and lymphatic vessels [24] [25]. In the MG thymus, the HEVs likely contribute to the
45
46 recruitment of B cells and antigen-presenting cells as these cells can be detected close to the HEVs
47
48 [26]. The production of auto-antibodies resulting from GC development usually precedes the disease
49
50 [27]. In MG thymuses, B cells appear to derive from an antigen-driven reaction [28]. These thymic B
51
52 cells can produce antibodies to AChR, as assessed by titration in culture supernatants of thymic cells
53
54 [29] or in the sera of immunodeficient mice grafted with MG thymic tissue [30, 31]. Importantly, anti-
55
56
57
58
59
60

1
2
3 AChR antibodies produced by MG thymic B cells are pathogenic since grafts of MG thymic fragments
4
5 could result in myasthenic symptoms in immunodeficient mice [32].
6

7
8 The increased number of B cells in the MG thymus is associated with increased expression of BAFF, a
9
10 factor supporting survival and differentiation of B cells [33]. Increased serum levels of BAFF are
11
12 found in MG as well as in several AIDs [34]. Overexpression of BAFF in mice results in increased B
13
14 cell numbers in spleen and lymph nodes, and a SLE-like autoimmune phenotype [35]. Inhibition of
15
16 BAFF reduces the severity of the ongoing disease, supporting its pathogenic role [36]. In humans, an
17
18 anti-BAFF monoclonal antibody (belimumab) has proven to be efficient in SLE and RA and is
19
20 approved for treatment of SLE [21]. In MG, a phase II clinical trial using this monoclonal antibody is
21
22 ongoing (ClinicalTrials.gov: NCT01480596).
23

24
25 Altogether, the development of GCs and the overexpression of BAFF are hallmarks of AIDs. The
26
27 efficiency of anti-BAFF therapy in animal models and patients suggests a pathogenic role of BAFF in
28
29 AIDs. Also, the presence of GCs in the pathogenic organs highlights its pivotal role in the recruitment
30
31 of inflammatory cells and initiation and the propagation of the disease.
32
33

34 35 **4. Origin of the defect of Treg cells** 36

37
38 Regulatory T (Treg) cells are of paramount importance to prevent excessive inflammation in various
39
40 organs. The lack of functional Tregs, in genetic diseases, including the scurfy mice and humans with
41
42 the IPEX syndrome, leads to a broad range of inflammatory disorders affecting various tissues [37].
43
44 As such, Treg cell defects have been considered as a primary cause of AIDs. However, one could ask
45
46 whether the Treg cell dysfunction exists before the onset of the disease, or is provoked by the
47
48 inflammatory event induced by the triggering components. The defect of Treg cells generally coexists
49
50 with the inflammatory processes suggesting several hypotheses: 1) the inflammation might develop
51
52 because of a poor regulation of the immune system, 2) the Treg cells could become inefficient because
53
54 of the inflammatory environment, 3) a common factor concomitantly leads to both effects.
55
56
57
58
59
60

1
2
3 According to the literature, several experimental findings support the hypothesis that Treg cell defects
4 in AIDs could be a consequence, and not necessarily a primary cause, of the disease. We will
5 summarize here these arguments:
6
7

8
9 1) A defect in Treg function can appear after immunization with an autoantigen in experimental
10 autoimmunity. For example, in the EAMG rat model, the induction of the disease by immunization
11 with torpedo-AChR results in a decreased frequency and suppressive activity of Treg cells in the
12 spleen and peripheral blood compared with control rats [38].
13
14
15
16

17
18 2) The fact that Treg cell defect is often concomitant with a resistance of Tconv cells to suppression
19 by normal Treg cells [39] suggests that the immune imbalance does not affect only the Treg cells, but
20 more likely the whole immune system. The resistance of Tconv cells is likely due to the inflammatory
21 microenvironment [40], and could be mediated by TNF- α . In MG cells, blocking TNF- α decreases
22 the resistance of thymic Tconv cells to suppression [7], supporting the hypothesis that inflammatory
23 molecules are, at least partially, responsible for the resistance of Tconv cells to suppression. In RA, T
24 cells become resistant to regulation at the site of inflammation, and this contributes to the altered
25 immune balance in the inflamed joints of RA patients [41].
26
27
28
29
30
31
32
33
34

35 3) Defects of Treg cells do not appear to be intrinsic as they can be reversed in vitro or in vivo. Anti-
36 inflammatory drugs such as dexamethasone were shown to restore the function of Treg cells [42].
37 Other immunosuppressive drugs, such as rapamycin can have a marked effect on Treg cell number
38 and function (reviewed in [43]). In many cases, as soon as AIDs patients are treated with anti-
39 inflammatory drugs, the Treg cell function is improved. The commonly used corticosteroid drug
40 improves Treg cell function in SLE [44], MG [45] and RA [46] patients. Intravenous
41 immunoglobulins that are commonly administrated in patients with AIDs appear to act, at least
42 partially, by restoring Treg cell function and number [47].
43
44
45
46
47
48
49
50

51 In MG animal models, Treg cell number and function are restored by therapeutic drugs. In mice, one
52 example is the therapy by a peptide inhibitor of the plasminogen activator system in tissue
53 plasminogen activator (TPA) $-/-$ mice that have a severe MG and defects in Treg cell numbers [48].
54 Following the injection of the peptide inhibitor, the disease severity is reduced, and Treg cell numbers
55
56
57
58
59
60

1
2
3 are increased. A second example is a therapy via intravenous immunoglobulins or a subfraction
4 including recombinant polyvalent IgG2a Fc (M045) in the classical model of EAMG induced by
5 immunization with torpedo AChR. The M045 treatment improves the course of the disease and causes
6 an expansion of the FoxP3+ Treg cell population [49].
7
8

9
10
11 Together, these data suggest that Treg cell defects in acquired AIDs are not necessarily pre-existing to
12 the triggering event. Since the experimental triggering events (immunization for example) in vivo are
13 different from the ones in natura, one major challenge will be to understand how predisposing factors
14 (genetic, vitamin D level, hormones, microbiota, etc.) could contribute to the Treg cell defects in
15 AIDs.
16
17
18
19
20
21

22 23 24 **5. How to explain the specificity of autoimmune diseases?**

25
26 Although frequent poly-autoimmunity is observed in families affected by AIDs, most often the
27 patients have only one specific disease. Once the immune system is overactivated, one could ask why
28 a patient will develop a particular disease and not another one.
29
30
31

32
33 Several non-mutually exclusive hypotheses could be proposed:
34

35
36 1) The role of HLA genes has been suspected for long. Each HLA molecule has a certain affinity for
37 antigen-derived peptides. For instance, a peptide from an autoantigen will fit into the peptide-binding
38 pocket of a particular HLA-DR allele, and the HLA-peptide complex will be recognized by the T-cell
39 receptor, while other HLA-DR molecules would not bind the same autoantigenic peptide with a high
40 affinity. However, this hypothesis does not explain why a certain HLA haplotype, e.g., HLA-DR3, is
41 the susceptibility locus for several AIDs, including SLE, Type 1 diabetes, autoimmune thyroiditis,
42 Sjogren's Syndrome and MG. One hypothesis could be that HLA-DR3 is more permissive than other
43 HLA molecules to the presentation of in situ-generated hybrid molecules containing self-peptides, a
44 phenomenon that was recently described for diabetes [50].
45
46
47
48
49
50
51
52
53

54
55 2) The nature of the triggering event could contribute to the specificity of the disease. Toll-like
56 receptors (TLR) are involved in the recognition by the innate immune system of a broad range of
57
58
59
60

1
2
3 microbial ligands that can induce a disease in several experimental models of autoimmunity, including
4 RA, diabetes, and atherosclerosis (Reviewed in [51]). It is worth-mentioning that some TLRs are more
5 specifically associated with some AIDs. For example, TLR2 or TLR4 polymorphisms are frequently
6 associated with RA, while TLR5 and TLR8 polymorphisms are associated with SLE and Sjogren's
7 syndrome (Reviewed in [51]). Alternatively, regardless of TLR polymorphisms, qualitative
8 environmental variations of TLR ligands may contribute to AIDs. For example, type 1 diabetes is
9 associated with a specific lipopolysaccharide, the microbial TLR4 ligand [52]. In MG, we have shown
10 that the TLR3 agonist poly(I:C), but no other TLR agonists, can upregulate the expression of α -AChR
11 in thymic cells and induce myasthenic symptoms when injected into mice [53]. Interestingly, poly(I:C)
12 does not affect the expression of other autoantigens, suggesting that poly(I:C) has a specific effect on
13 AChR.
14
15
16
17
18
19
20
21
22
23
24

25
26 3) The nature of the organ affected by the triggering molecule is likely essential for the specificity of
27 the autoimmune reaction. Infections can occur in any organ, but taking into account the cellular and
28 molecular specificities of each organ, the functional consequences of a given perturbation could be
29 very different. This assumption is particularly relevant in the perspective of the eQTLs that are genetic
30 variants associated with the transcriptional expression of one or several genes. Indeed, more than 10%
31 of eQTLs can be context specific, being selectively active in specific tissues or cell types [54]. A
32 recent study found that about half of eQTLs are tissue-specific [55], highlighting the importance of
33 considering tissues or cells of interest to understand how eQTLs may influence AIDs. Thus, a
34 triggering event occurring in an organ that permits the excessive transcriptional expression of genes
35 involved in the immune response could explain the targeting of this specific organ.
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **6. Why are AIDs chronic?**

50
51 While AIDs are generally incurable chronic diseases, transient autoimmunity can also be swiftly
52 induced by environmental triggers (notably drugs) and disappear upon their withdrawal. This fact
53 indicates that chronicity is not a necessary consequence of autoimmunity. Many drugs can induce the
54
55
56
57
58
59
60

1
2
3 production of antibodies and autoimmune symptoms although the presence of autoantibodies is much
4 more frequent than the appearance of symptoms (Reviewed in [56]).
5
6

7
8 In the case of SLE, a very common AID, a drug-induced disease was first described in 1945 after the
9 treatment with sulfadiazine. Since then, a large number of drugs (more than 100) have been implicated
10 in inducing lupus. Drug-induced SLE accounts for about 10% of all SLE cases and its presentation is
11 similar to idiopathic SLE, but the symptoms usually resolve within weeks after drug withdrawal [57].
12
13 Thus, autoimmune diseases are not inevitably chronic. In drug-induced diseases, it is possible that the
14 pathogenic effects are minimal as the disease is at an early stage. If this hypothesis is exact, an early
15 diagnostic will provide a better chance of reversing the disease.
16
17
18
19
20
21

22 While the findings exposed above indicate that chronicity is not an inevitable consequence of
23 autoimmunity, it is likely that autoimmunity results from a chronic imbalance involving both
24 environmental and intrinsic factors. Several non-mutually hypotheses could explain the chronicity of
25 the autoimmune response:
26
27
28
29

30
31 1) An ongoing antigenic availability linked to the maintenance of the GCs could account for the
32 chronicity of the production of the autoantibodies. In physiological conditions, GC reactions disappear
33 few weeks after their induction, while in AIDs these structures are very stable. For example, in AChR-
34 MG patients, GCs could be found in the thymus of MG patients even ten years or more after disease
35 onset, suggesting that B cells migrate continuously to the thymus [4]. Since the autoantigen (AChR) is
36 expressed in several thymic cell types [58, 59] and could be upregulated by interferons [33], a high
37 expression of the autoantigen will promote its availability. The stability of the GCs could be due to a
38 defective mechanism of apoptosis within the GC. Indeed, the resolution phase of GCs is associated
39 with high level of apoptosis [60]. While the anti-apoptotic factor Bcl-2 is not expressed in GCs of
40 control tonsil, it is expressed in thymic GCs of MG patients where it may prevent cell apoptosis [61].
41
42
43
44
45
46
47
48
49
50

51
52 2) The resolution of inflammation that is a complex coordinated process to return to tissue
53 homeostasis could be defective. Resolution of inflammation appears to be a bridge between innate and
54 adaptive immunity. An incomplete resolution of the initial acute response that does not engage a
55 proper adaptive immune response could lead to chronic inflammation [62]. Inflammation resolution
56
57
58
59
60

1
2
3 process is controlled by a variety of endogenous mediators that include specialized proresolving
4 mediators such as lipoxins and resolvins, protein/peptide mediators, gases, as well as nucleotides [63].
5
6 As a proof of concept, in the murine model of autoimmune arthritis, the resolution of inflammation
7 that is disrupted by cyclooxygenase-2 inhibition is restored by prostaglandin E2-mediated lipoxin A4
8 production [64]. In another model of murine inflammatory arthritis, the anti-arthritic properties of
9 resolvin D1 could be demonstrated [65]. In MG, in a recent analysis of the transcriptome and
10 methylome of peripheral monocytes in monozygotic (MZ) twins discordant and concordant for MG,
11 we showed a decreased expression of several transcripts associated with immune homeostasis and
12 inflammation resolution. Thus, the impaired monocyte function in MG and the decreased expression
13 of genes associated with inflammation resolution could contribute to the chronicity of the disease.
14 These examples show that the resolution of inflammation could be less efficient in AIDs patients than
15 in other individuals, raising the susceptibility of developing a chronic disease.
16
17

18
19
20
21
22
23
24
25
26
27
28 3) Immune check-points are major cell surface inhibitory receptors that may also be involved in the
29 chronicity of AIDs. Intracellular checkpoints contribute to limit the activation of inflammatory cells
30 [66]. Thus a reduced expression of these molecules could prevent an efficient regulation of the
31 immune cell activation. PD-1 SNPs have been associated with several AIDs including SLE and RA
32 [67]. However, it is known that SNPs only rarely fully explain a phenotype and that other genetic
33 variants should be concomitantly taken into account. This is illustrated by the PD-1 deficiency in
34 mice, which results in the development of a lupus-like autoimmune disease or a cardiomyopathy
35 depending on the genotype background [68, 69]. Immune checkpoint blockers (ICBs) have recently
36 proven their remarkable efficiency against melanoma and non-small cell lung carcinoma, but they can
37 induce immune-related adverse events. In addition to rashes, hepatitis or colitis, ICBs have been
38 associated with the development or the exacerbation of MG in 22 cases [70]. This observation is all
39 the more striking as the CTLA-4 gene is strongly associated with MG [71]. Interestingly, while anti-
40 CTLA-4 treatments have been linked to the development of MG in some cases, humans bearing
41 mutations of CTLA-4 develop a spectrum of autoimmune syndromes distinct from MG [72, 73].
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 Overall, this may be sufficient to precipitate autoimmunity in a predisposing ground.
57
58
59
60

1
2
3 4) As discussed above, Treg cell defects could be induced by the high level of inflammation.
4
5 However, in a highly inflammatory environment, conventional T cells might be out of control, and
6
7 resistant to suppression. If the Treg are unable to reduce the proliferation of Tconv cells, this will
8
9 predictably result in a chronic pathological process.

10
11 Inflammation can also lead to a re-programming of Treg cells into pro-inflammatory Th17 cells (ex-
12
13 Tregs), illustrating a vicious circle whereby inflammation (that can be induced by Th17 cells) leads to
14
15 more inflammation. The pathogenic role of ex-Tregs has been demonstrated in various experimental
16
17 autoimmune models including RA [74]. Conversely, resolution of inflammation is associated with the
18
19 transdifferentiation of Th17 cells into Tregs [75]. However, since the defective Treg cells are unable to
20
21 reduce the inflammation level, the autoimmune response is maintained at a high level, contributing to
22
23 the chronicity of the disease
24
25
26
27
28

29 **Conclusion**

30
31 AIDs are typically complex diseases constituting major intellectual challenges for clinicians and
32
33 biologists. The most advanced methods of genetic screening or immune screening seemed to be
34
35 promising but did not thus far enable to fully understand the causes of AIDs. However, it is of utmost
36
37 importance that we now better apprehend to which extent AIDs could be complex. Genetically, it is
38
39 now clear that polygenic explanations did not fulfill expectations, and that more efforts are needed to
40
41 understand how the interplay of environmental clues may have a phenotypic impact. Immunologically,
42
43 it is of utmost importance to distinguish co-occurring dysregulations from potentially causing
44
45 perturbations that may even have come back to normal states. Collectively, AIDs remain challenging
46
47 to study, and interdisciplinary approaches will be more than ever essential to unravel the complexity
48
49 and provide better and more personalized therapeutic approaches in the future.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1: Autoimmune diseases: some common features

Cloud of terms frequently associated with Myasthenia Gravis, as well as with other autoimmune diseases. As the font of a term is bigger, as the number of AIDs associated with this term is higher.

Bibliography

- [1] Anaya JM, Ramirez-Santana C, Alzate MA, Molano-Gonzalez N, Rojas-Villarraga A. *The Autoimmune Ecology*. *Frontiers in immunology*;7:139.2016
- [2] Generali E, Ceribelli A, Stazi MA, Selmi C. *Lessons learned from twins in autoimmune and chronic inflammatory diseases*. *Journal of autoimmunity*;83:51-61.2017
- [3] Le Panse R, Cizeron-Clairac G, Bismuth J, Berrih-Aknin S. *Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia*. *Journal of immunology*;177:7868-79.2006
- [4] Truffault F, de Montpreville V, Eymard B, Sharshar T, Le Panse R, Berrih-Aknin S. *Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review*. *Clin Rev Allergy Immunol*;52:108-24.2017
- [5] Huang da W, Sherman BT, Lempicki RA. *Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources*. *Nat Protoc*;4:44-57.2009
- [6] Berrih-Aknin S. *Myasthenia Gravis: paradox versus paradigm in autoimmunity*. *Journal of autoimmunity*;52:1-28.2014
- [7] Gradolatto A, Nazzal D, Truffault F, Bismuth J, Fadel E, Foti M et al. *Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-alpha*. *Journal of autoimmunity*;52:53-63.2014
- [8] Avidan N, Le Panse R, Berrih-Aknin S, Miller A. *Genetic basis of myasthenia gravis - a comprehensive review*. *Journal of autoimmunity*;52:146-53.2014
- [9] Ishigaki K, Kochi Y, Suzuki A, Tsuchida Y, Tsuchiya H, Sumitomo S et al. *Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis*. *Nature genetics*;49:1120-5.2017
- [10] Gabrielsen IS, Amundsen SS, Helgeland H, Flam ST, Hatinoor N, Holm K et al. *Genetic risk variants for autoimmune diseases that influence gene expression in thymus*. *Human molecular genetics*;25:3117-24.2016
- [11] Boyle EA, Li YI, Pritchard JK. *An Expanded View of Complex Traits: From Polygenic to Omnigenic*. *Cell*;169:1177-86.2017
- [12] Zheng J, Ibrahim S, Petersen F, Yu X. *Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue*. *Genes and immunity*;13:641-52.2012
- [13] Lefvert AK, Zhao Y, Ramanujam R, Yu S, Pirskanen R, Hammarstrom L. *PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis*. *J Neuroimmunol*;197:110-3.2008
- [14] Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T. *Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP*. *European journal of immunology*;29:3845-54.1999
- [15] Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, Chan AC. *PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells*. *Science*;303:685-9.2004
- [16] Burn GL, Svensson L, Sanchez-Blanco C, Saini M, Cope AP. *Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?* *FEBS Lett*;585:3689-98.2011
- [17] Menard L, Saadoun D, Isnardi I, Ng YS, Meyers G, Massad C et al. *The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans*. *J Clin Invest*;121:3635-44.2011
- [18] Maine CJ, Marquardt K, Cheung J, Sherman La. *PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells*. *Journal of immunology (Baltimore, Md : 1950)*;192:1415-24.2014
- [19] Natkunam Y. *The biology of the germinal center*. *Hematology Am Soc Hematol Educ Program*:210-5.2007

- 1
2
3 [20] Aloisi F, Pujol-Borrell R. *Lymphoid neogenesis in chronic inflammatory diseases*. Nature reviews Immunology;6:205-17.2006
- 4 [21] Berrih-Aknin S, Ragheb S, Le Panse R, Lisak RP. *Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis*. Autoimmun Rev;12:885-93.2013
- 5 [22] Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R et al. *Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG*. Annals of neurology;57:444-8.2005
- 6 [23] Le Panse R, Bismuth J, Cizeron-Clairac G, Weiss JM, Cufi P, Dartevielle P et al. *Thymic remodeling associated with hyperplasia in myasthenia gravis*. Autoimmunity;43:401-12.2010
- 7 [24] Weiss JM, Cufi P, Le Panse R, Berrih-Aknin S. *The thymus in autoimmune Myasthenia Gravis: Paradigm for a tertiary lymphoid organ*. Rev Neurol (Paris);169:640-9.2013
- 8 [25] Berrih-Aknin S, Ruhlmann N, Bismuth J, Cizeron-Clairac G, Zelman E, Shachar I et al. *CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia*. Annals of neurology;66:521-31.2009
- 9 [26] Weiss JM, Cufi P, Bismuth J, Eymard B, Fadel E, Berrih-Aknin S et al. *SDF-1/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients*. Immunobiology;218:373-81.2013
- 10 [27] Ma WT, Chang C, Gershwin ME, Lian ZX. *Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review*. Journal of autoimmunity;83:95-112.2017
- 11 [28] Zuckerman NS, Howard WA, Bismuth J, Gibson K, Edelman H, Berrih-Aknin S et al. *Ectopic GC in the thymus of myasthenia gravis patients show characteristics of normal GC*. European journal of immunology;40:1150-61.2010
- 12 [29] Leprince C, Cohen-Kaminsky S, Berrih-Aknin S, Vernet-Der Garabedian B, Treton D, Galanaud P et al. *Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis*. Journal of immunology;145:2115-22.1990
- 13 [30] Schonbeck S, Padberg F, Hohlfeld R, Wekerle H. *Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis*. J Clin Invest;90:245-50.1992
- 14 [31] Aissaoui A, Klingel-Schmitt I, Couderc J, Chateau D, Romagne F, Jambou F et al. *Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis*. Annals of neurology;46:559-67.1999
- 15 [32] Sudres M, Maurer M, Robinet M, Bismuth J, Truffault F, Girard D et al. *Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model*. JCI insight;2:e89665.2017
- 16 [33] Cufi P, Dragin N, Ruhlmann N, Weiss JM, Fadel E, Serraf A et al. *Central role of interferon-beta in thymic events leading to myasthenia gravis*. Journal of autoimmunity;52:44-52.2014
- 17 [34] Kim JY, Yang Y, Moon JS, Lee EY, So SH, Lee HS et al. *Serum BAFF expression in patients with myasthenia gravis*. J Neuroimmunol;199:151-4.2008
- 18 [35] Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P et al. *Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations*. J Exp Med;190:1697-710.1999
- 19 [36] Davidson A. *Targeting BAFF in autoimmunity*. Curr Opin Immunol;22:732-9.2010
- 20 [37] Torgerson TR, Ochs HD. *Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells*. The Journal of allergy and clinical immunology;120:744-50; quiz 51-2.2007
- 21 [38] Gertel-Lapter S, Mizrachi K, Berrih-Aknin S, Fuchs S, Souroujon MC. *Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model*. Autoimmun Rev;12:894-903.2013
- 22 [39] Buckner JH. *Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases*. Nature reviews Immunology;10:849-59.2010
- 23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [40] Wehrens EJ, Mijnheer G, Duurland CL, Klein M, Meerding J, van Loosdregt J *et al.* *Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells.* *Blood*;118:3538-48.2011
- 4
5 [41] Wehrens EJ, Prakken BJ, van Wijk F. *T cells out of control--impaired immune regulation in the inflamed joint.* *Nat Rev Rheumatol*;9:34-42.2013
- 6
7 [42] Hu Y, Tian W, Zhang LL, Liu H, Yin GP, He BS *et al.* *Function of regulatory T-cells improved by dexamethasone in Graves' disease.* *Eur J Endocrinol*;166:641-6.2012
- 8
9 [43] Zhang C, Shan J, Feng L, Lu J, Xiao Z, Luo L *et al.* *The effects of immunosuppressive drugs on CD4(+) CD25(+) regulatory T cells: a systematic review of clinical and basic research.* *J Evid Based Med*;3:117-29.2010
- 10
11 [44] Suarez A, Lopez P, Gomez J, Gutierrez C. *Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids.* *Annals of the rheumatic diseases*;65:1512-7.2006
- 12
13 [45] Luther C, Adamopoulou E, Stoeckle C, Brucklacher-Waldert V, Rosenkranz D, Stoltze L *et al.* *Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients.* *Journal of immunology*;183:841-8.2009
- 14
15 [46] Alunno A, Manetti M, Caterbi S, Ibba-Manneschi L, Bistoni O, Bartoloni E *et al.* *Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications.* *Mediators of inflammation*;2015:751793.2015
- 16
17 [47] Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J *et al.* *Immunomodulation by intravenous immunoglobulin: role of regulatory T cells.* *J Clin Immunol*;30 Suppl 1:S4-8.2010
- 18
19 [48] Gur-Wahnon D, Mizrachi T, Wald-Altman S, Al-Roof Higazi A, Brenner T. *Tissue plasminogen activator involvement in experimental autoimmune myasthenia gravis: Aggravation and therapeutic potential.* *Journal of autoimmunity.*2014
- 20
21 [49] Thiruppathi M, Sheng JR, Li L, Prabhakar BS, Merigglioli MN. *Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.* *Journal of autoimmunity.*2014
- 22
23 [50] DeLong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisdorph R *et al.* *Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion.* *Science*;351:711-4.2016
- 24
25 [51] Marshak-Rothstein A. *Toll-like receptors in systemic autoimmune disease.* *Nature reviews Immunology*;6:823-35.2006
- 26
27 [52] Vatanen T, Kostic AD, d'Hennezel E, Siljander H, Franzosa EA, Yassour M *et al.* *Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans.* *Cell*;165:1551.2016
- 28
29 [53] Cufi P, Dragin N, Weiss JM, Martinez-Martinez P, De Baets MH, Roussin R *et al.* *Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis.* *Annals of neurology*;73:281-93.2013
- 30
31 [54] Zhernakova DV, Deelen P, Vermaat M, van Iterson M, van Galen M, Arindrarto W *et al.* *Identification of context-dependent expression quantitative trait loci in whole blood.* *Nature genetics*;49:139-45.2017
- 32
33 [55] Consortium GT. *Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans.* *Science*;348:648-60.2015
- 34
35 [56] Chang C, Gershwin ME. *Drugs and autoimmunity--a contemporary review and mechanistic approach.* *Journal of autoimmunity*;34:J266-75.2010
- 36
37 [57] Xiao X, Chang C. *Diagnosis and classification of drug-induced autoimmunity (DIA).* *Journal of autoimmunity*;48-49:66-72.2014
- 38
39 [58] Wakkach A, Poea S, Chastre E, Gespach C, Lecerf F, De La Porte S *et al.* *Establishment of a human thymic myoid cell line. Phenotypic and functional characteristics.* *The American journal of pathology*;155:1229-40.1999
- 40
41 [59] Wakkach A, Guyon T, Bruand C, Tzartos S, Cohen-Kaminsky S, Berrih-Aknin S. *Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis.* *Journal of immunology*;157:3752-60.1996
- 42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [60] Wittenbrink N, Klein A, Weiser AA, Schuchhardt J, Or-Guil M. *Is there a typical*
4 *germinal center? A large-scale immunohistological study on the cellular*
5 *composition of germinal centers during the hapten-carrier-driven primary immune*
6 *response in mice.* Journal of immunology;187:6185-96.2011
- 7 [61] Shiono H, Fujii Y, Okumura M, Takeuchi Y, Inoue M, Matsuda H. *Failure to down-*
8 *regulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis.*
9 European journal of immunology;27:805-9.1997
- 10 [62] Fullerton JN, Gilroy DW. *Resolution of inflammation: a new therapeutic frontier.*
11 Nature reviews Drug discovery;15:551-67.2016
- 12 [63] Fredman G, Tabas I. *Boosting Inflammation Resolution in Atherosclerosis: The*
13 *Next Frontier for Therapy.* The American journal of pathology;187:1211-21.2017
- 14 [64] Chan MM, Moore AR. *Resolution of inflammation in murine autoimmune arthritis is*
15 *disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-*
16 *mediated lipoxin A4 production.* Journal of immunology;184:6418-26.2010
- 17 [65] Norling LV, Headland SE, Dalli J, Arnardottir HH, Haworth O, Jones HR et al.
18 *Proresolving and cartilage-protective actions of resolvin D1 in inflammatory*
19 *arthritis.* JCI insight;1:e85922.2016
- 20 [66] Lawrence T, Gilroy DW. *Chronic inflammation: a failure of resolution?*
21 International journal of experimental pathology;88:85-94.2007
- 22 [67] Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N. *PD-1/PD-L and*
23 *autoimmunity: A growing relationship.* Cellular immunology;310:27-41.2016
- 24 [68] Nishimura H, Nose M, Hiai H, Minato N, Honjo T. *Development of lupus-like*
25 *autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-*
26 *carrying immunoreceptor.* Immunity;11:141-51.1999
- 27 [69] Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A et al.
28 *Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.*
29 Science;291:319-22.2001
- 30 [70] Makarios D, Horwood K, Coward JIG. *Myasthenia gravis: An emerging toxicity of*
31 *immune checkpoint inhibitors.* European journal of cancer (Oxford, England :
32 1990);82:128-36.2017
- 33 [71] Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA et al. *A*
34 *genome-wide association study of myasthenia gravis.* JAMA neurology;72:396-
35 404.2015
- 36 [72] Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G et al.
37 *Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune*
38 *disease.* Nature;423:506-11.2003
- 39 [73] Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A et al. *Autosomal*
40 *dominant immune dysregulation syndrome in humans with CTLA4 mutations.*
41 Nature medicine;20:1410-6.2014
- 42 [74] Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T et al.
43 *Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis.*
44 Nature medicine;20:62-8.2014
- 45 [75] Gagliani N, Amezcu Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW et al.
46 *Th17 cells transdifferentiate into regulatory T cells during resolution of*
47 *inflammation.* Nature;523:221-5.2015
- 48
49
50
51
52
53
54
55
56
57
58
59
60

| Term | Gene number | Fold enrichment | P value |
|------------------------------|-------------|-----------------|---------|
| Systemic Lupus Erythematosus | 24 | 2.04 | 0.00071 |
| Graves' Disease | 11 | 2.84 | 0.0027 |
| Crohn's Disease | 14 | 2.22 | 0.0065 |
| Multiple Sclerosis | 30 | 1.58 | 0.0092 |
| Celiac Disease | 14 | 2.03 | 0.014 |
| Primary Biliary Cirrhosis | 7 | 2.87 | 0.025 |
| Sarcoidosis | 11 | 2.07 | 0.030 |
| Systemic Sclerosis | 10 | 2.18 | 0.030 |
| Ulcerative Solitis | 10 | 2.11 | 0.037 |
| Sjogren's Syndrome | 7 | 2.57 | 0.043 |

Table 1. AID genetic associations shared with EOMG.

A similarity was found in the category of “Genetic Association Database” that is a database of genetic association data from complex diseases and disorders. Diseases that show significant association with EOMG are listed. The “gene number” column indicates the number of genes common between MG and the other autoimmune diseases. The “fold enrichment » column indicates the ratio between two percentages: the percentage of genes of on term in the hit list (deregulated gene list in EOMG) divided by the percentage of genes of the same term in the list of genes of the category “AID genetic associations”. As an example, the percentage of genes associated with systemic lupus erythematosus is around 2% in the whole list (category AID genetic associations) and 4% in the hit list. Thus the ratio between these two percentages is 2. In other words, when the ratio is 1, that indicates no enrichment. Here the fold-enrichments are between 1.58 to 2.87, showing a significant enrichment for the diseases shown in the table.

Adapted from ref 4 with Springer permission.

| Gene-Id | Name | Number of diseases | Change in MG |
|---------|--|--------------------|--------------|
| 929 | CD14 molecule | 3 | UP |
| 930 | CD19 molecule | 3 | UP |
| 941 | CD80 molecule | 4 | DOWN |
| 6352 | Chemokine (C-C motif) ligand 5 | 4 | UP |
| 356 | Fas ligand (TNF superfamily, member 6) | 4 | UP |
| 3383 | Intercellular adhesion molecule 1 | 5 | DOWN |
| 3659 | Interferon regulatory factor 1 | 4 | DOWN |
| 3553 | Interleukin 1, beta | 6 | UP |
| 3117 | Major histocompatibility complex, class II, DQ alpha 1 | 6 | UP |
| 3119 | Major histocompatibility complex, class II, DQ beta 1 | 9 | UP |
| 3122 | Major histocompatibility complex, class II, DR alpha | 5 | UP |
| 3123 | Major histocompatibility complex, class II, DR beta 1 | 10 | UP |
| 4846 | Nitric oxide synthase 3 (endothelial cell) | 4 | UP |
| 4790 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | 4 | DOWN |
| 26191 | Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) | 9 | DOWN |
| 7421 | Vitamin D (1,25- dihydroxyvitamin D3) receptor | 3 | UP |

Table 2. List of the genes dysregulated in EOMG as well as in other autoimmune diseases.

Many genes dysregulated in EOMG are also associated with other autoimmune diseases. Some of them could be associated with many autoimmune diseases such as MHC class II genes or PTPN22. The number of diseases presenting the dysregulated genes is indicated in the column “number of diseases”. Whether the expression of the gene is upregulated or downregulated in MG is indicated in the last column. *Adapted from ref 4 with Springer permission.*

| Disease | Target Organ | Organ with ectopic GCs |
|------------------------------|---------------------|--|
| Myasthenia Gravis | Muscle | Thymus |
| Multiple Sclerosis | Brain | Brain |
| Rheumatoid Arthritis | Synovium | Synovium |
| Sjogren's Syndrome | Salivary glands | Salivary glands |
| Systemic Lupus Erythematosus | Systemic | Pre-germinal centers and plasma cell precursors in the blood |
| Autoimmune Thyroiditis | Thyroid | Thyroid |
| T1 Diabetes Mellitus | Pancreas | Pancreas (NOD mice) |

Table 3: Germinal Centers in AIDs. Many AIDs display ectopic GCs in their target organs, while in MG, the ectopic GCs are found in the thymus and not in the target organ, the muscle.

